Abstract: Chronic kidney disease-mineral and bone disorders (CKD-MBD) are common and serious complications in patients with CKD.  Denosumab (DMab) is an inhibitor of the receptor activator of nuclear factor-kappa B ligand (RANKL) used for the treatment of postmenopausal osteoporosis. It has been applied clinically for male or female CKD patients with or without dialysis. DMab used in the treatment of CKD-MBD may produce the effects on bone metabolism biomarkers, bone mass, and vascular calcification. Here we review the safety and efficacy of DMab in CKD patients and summarize the clinical experience of the RANKL inhibitor in the treatment of CKD-MBD.

Key words: Denosumab, Dialysis, Chronic kidney disease-mineral and bone disorder, Bone mineral density, Hypocalcemia